Fiera Capital Corp Has $30.44 Million Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Fiera Capital Corp decreased its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 8.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,184,467 shares of the company's stock after selling 105,353 shares during the period. Fiera Capital Corp owned approximately 1.37% of IDEAYA Biosciences worth $30,441,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. WCM Investment Management LLC purchased a new stake in shares of IDEAYA Biosciences during the fourth quarter worth about $6,030,000. abrdn plc boosted its position in shares of IDEAYA Biosciences by 31.7% in the fourth quarter. abrdn plc now owns 306,723 shares of the company's stock worth $7,883,000 after acquiring an additional 73,893 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of IDEAYA Biosciences by 12.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,327 shares of the company's stock worth $471,000 after acquiring an additional 2,078 shares during the last quarter. R Squared Ltd acquired a new position in IDEAYA Biosciences during the fourth quarter valued at approximately $35,000. Finally, KBC Group NV lifted its position in IDEAYA Biosciences by 84.6% during the fourth quarter. KBC Group NV now owns 4,197 shares of the company's stock valued at $108,000 after buying an additional 1,923 shares in the last quarter. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Stock Performance

NASDAQ IDYA traded up $0.24 on Monday, reaching $21.00. The company's stock had a trading volume of 1,427,577 shares, compared to its average volume of 787,501. IDEAYA Biosciences, Inc. has a twelve month low of $20.63 and a twelve month high of $47.74. The stock has a market cap of $1.82 billion, a PE ratio of -9.01 and a beta of 0.82. The firm's 50 day moving average is $24.36 and its two-hundred day moving average is $29.79.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The business had revenue of $7.00 million during the quarter, compared to analysts' expectations of $7.00 million. Equities research analysts anticipate that IDEAYA Biosciences, Inc. will post -2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Royal Bank of Canada reissued an "outperform" rating and set a $61.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. UBS Group initiated coverage on shares of IDEAYA Biosciences in a research note on Thursday, October 24th. They issued a "buy" rating and a $50.00 price target for the company. Leerink Partnrs lowered shares of IDEAYA Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, November 5th. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Finally, Wedbush restated an "outperform" rating and set a $52.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, IDEAYA Biosciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $53.58.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.